News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen Idec, Inc. (Massachusetts) (BIIB)'s Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS


10/10/2012 8:51:21 AM

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) will have extensive data from the company’s leading multiple sclerosis (MS) franchise presented during the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10 – 13. Fifty-three poster and platform presentations will further showcase Biogen Idec’s commitment to advancing the treatment of MS and improving the lives of people living with the disease around the world.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES